Human natural killer cells and cytotoxic T lymphocytes require cell surface carbohydrate determinants for lytic function.
Cloned and uncloned populations of natural killer (NK) cells and cytotoxic T lymphocytes (CTL) were treated with tunicamycin, an antibiotic that inhibits N-linked glycosylation, in order to study the potential role of cell surface carbohydrate determinants in lytic function. It is shown that tunicamycin-treated NK and CTL effector cells lose killer function in a dose-dependent manner. This effect is reversible; cells washed free of tunicamycin begin to recover their killer activity within 2 to 3 days after initial treatment. Conjugate experiments indicate that killer-target cell binding is not affected by tunicamycin treatment of the NK cells. It is also shown that tunicamycin treatment of target cells does not significantly affect their ability to be lysed by NK or CTL effector cells. These studies provide evidence that carbohydrate determinants are important in the lytic mechanism of both CTL and NK cells, rather than in specific effector-target cell binding.
D000954:Antigens, Surface / Q000032:analysis / Q000276:immunology*; D050260:Carbohydrate Metabolism; D002241:Carbohydrates / Q000032:analysis / Q000276:immunology*; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008565:Membrane Proteins / Q000378:metabolism; D010835:Phytohemagglutinins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D014415:Tunicamycin / Q000494:pharmacology
D000954:Antigens, Surface; D002241:Carbohydrates; D006023:Glycoproteins; D008565:Membrane Proteins; D010835:Phytohemagglutinins; D014415:Tunicamycin